Janux Therapeutics Inc. (JANX)
NASDAQ: JANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
JANX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $616.73M
- EPS (TTM)
- -$1.59
- Dividend yield
- None
- 52-week range
- 10.05 – 35.34
- Day range
- 10.05 – 10.54
- Volume / Avg
- 1.11M / 961.56K
- Beta
- —
- Shares outstanding
- 61.18M
52-week range
JANX stock today
Janux Therapeutics (JANX) closed at $10.08 on Nov 20, down 2.04% (-$0.21), versus the S&P 500's 3.70% decline. Shares are 71.5% below their 52-week high of $35.34, set on Nov 26, 2025 and 0.3% above the 52-week low of $10.05, near the bottom of the past year's range. JANX is down 27.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 65.0%.
Janux Therapeutics has posted a net loss over the last twelve months (EPS of -$1.59), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Janux Therapeutics
Company profileJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. David Alan Campbell Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 114
- IPO year
- 2021
- Website
- januxrx.com
Financial highlights
Full financialsIn fiscal 2025, Janux Therapeutics generated $10.0 million in revenue, down 5.6% from fiscal 2024, its first annual decline since 2023. Janux Therapeutics reported a net loss of $113.6 million, compared with a loss of $69.0 million a year earlier. Operating margin was -1576.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $10.00M | $10.59M | $8.08M | $8.61M | $3.64M |
| Growth | -5.55% | +30.99% | -6.14% | +136.79% | — |
| Net income | $-113.63M | $-68.99M | $-58.29M | $-63.06M | $-32.67M |
| EPS (diluted) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 |
Analyst forecast
ForecastConsensus (18 analysts)
strong_buy
Avg. price target
$33.14+228.77%
- Strong buy 2
- Buy 13
- Hold 2
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.34 vs $-0.45
- Surprise
- +24.44%
JANX news
All JANX news- Janux Therapeutics GAAP EPS of -$0.34 beats by $0.14, revenue of $9.29M beats by $2.87MSeeking Alpha
- Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business HighlightsBusiness Wire
- Janux Therapeutics stock may move 6.3% on earnings releaseInvesting.com
- Notable Thursday Option Activity: SOLS, JANX, UCTTNasdaqSOLS, JANX, UCTT
- Ensign Group (ENSG) Beats Q3 Earnings EstimatesNasdaqENSG, JANX
- Notable Wednesday Option Activity: PANW, JANX, ASSTNasdaqPANW, JANX, ASST
- The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and JanuxNasdaqNVS, PFE, JANX, CADL
- 4 Prostate Cancer Drug Stocks to Watch During Awareness MonthNasdaqNVS, PFE, JANX, CADL
Janux Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs JANX |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs JANX |
| KURAKura Oncology Inc. | 6.91 | -5.99% | $634.88M | vs JANX |
| ANNXAnnexon Inc. | 3.10 | -9.09% | $591.37M | vs JANX |
| SGMTSagimet Biosciences Inc. Series A | 9.08 | -5.61% | $648.02M | vs JANX |
| IMMXImmix Biopharma Inc. | 6.96 | -1.14% | $583.33M | vs JANX |
| DSGNDesign Therapeutics Inc. | 9.02 | -3.22% | $577.61M | vs JANX |
| NVCTNuvectis Pharma Inc. | 19.39 | -2.27% | $666.80M | vs JANX |
Indexes, lists and sector
Janux Therapeutics stock FAQ
What is Janux Therapeutics's stock price today?
JANX last traded at $10.08 as of Nov 20, 4:00 PM EST, down 2.04% on the day. Prices are delayed at least 15 minutes.
Who is Janux Therapeutics's CEO?
Dr. David Alan Campbell Ph.D. is the chief executive officer of Janux Therapeutics Inc., which has about 114 employees.
What is the JANX 52-week high?
The 52-week high for JANX is $35.34 and the 52-week low is $10.05. The stock is currently 71.5% below its high.